Bruker Corporation
Financials
Valuation Metrics
Bruker Corporation's Market Cap is $9.35B. At end of 2025 it was $7.16B. Ranked #953 of 3,121 in US market (top 31%), #308 of 1,463 on NASDAQ (top 21%), #70 of 205 in Health Care Equipment & Services (top 34%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $9.35B | US#953/3,121 Sec#70/205 |
| Revenue | $3.50B | US#1,090/3,121 Sec#64/205 |
| Net Income | $-71M | US—/3,121 Sec—/205 |
| Total Assets | $6.05B | US#1,308/3,121 Sec#58/205 |
| Net Assets | $2.40B | US#1,123/3,121 Sec#59/205 |
| Employees | 11,085 | US#812/3,121 Sec#61/205 |
| Value | ||
| P/B | 3.89x | US#2,019/3,121 Sec#117/205 |
| P/S | 2.67x | US#1,593/3,121 Sec#112/205 |
| EV/EBITDA | 44.72x | US#2,347/3,121 Sec#126/205 |
| FCF Yield | 1.00% | US#2,185/3,121 Sec#131/205 |
| Profitability | ||
| ROE | -2.97% | US#2,217/3,121 Sec#121/205 |
| ROA | -1.18% | US#2,323/3,121 Sec#126/205 |
| Op. Margin | 3.61% | US#2,121/3,121 Sec#115/205 |
| Revenue Growth | 1.65% | US#2,118/3,121 Sec#157/205 |
| Earnings Growth | -189.45% | US#1,962/3,121 Sec#101/205 |
| Financial Health | ||
| Debt Ratio | 151.40% | US#1,508/3,121 Sec#134/205 |
| Total Debt | $1.92B | US#1,201/3,121 Sec#61/205 |
| FCF | $94M | US#1,760/3,121 Sec#103/205 |
| Cash | $185M | US#1,796/3,121 Sec#109/205 |
| Current Ratio | 1.85x | US#1,345/3,121 Sec#116/205 |
| Net Debt/EBITDA | 6.99x | US#2,247/3,121 Sec#133/205 |
| Dividend | ||
| Div. Yield | 0.35% | US#1,590/3,121 Sec#48/205 |
| Div. Growth | -25.90% | US—/3,121 Sec—/205 |
| Performance | ||
| 1Y Return | 85.03% | US#230/3,121 Sec#24/205 |
| 1M Return | 4.69% | US#217/3,121 Sec#32/205 |
| From 52W High | -5.97% | US#187/3,121 Sec#25/205 |
| 1Y MDD | -39.85% | US#2,008/3,121 Sec#115/205 |
| Trading | ||
| Volume | 1,656,332 shares | US#590/3,121 Sec#30/205 |
| Trading Value | $102M | US#483/3,121 Sec#42/205 |
| Per Share | ||
| EPS | $-0.47 | US—/3,121 Sec—/205 |
| BPS | $15.77 | US#1,482/3,121 Sec#80/205 |
Company Info
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.